Propanc Biopharma, Inc.
About Propanc Biopharma, Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$58.9M
- Total assets
- $19.6M
- Market cap
- $3.3M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.3M
- Shares outstanding
- 2.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 15, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $58.9M.
- Trading 99% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Propanc Biopharma, Inc..
Write a review
News about Propanc Biopharma, Inc.
News & sentiment via Polygon.io
